Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of hiv-1 broad neutralizing antibodies 2f5 and 4e10

Journal of Immunology

Volumn 191, Issue 3, 2013, Pages 1260-1275

  Chen, Yao ^a   Zhang, Jinsong ^a   Hwang, Kwan Ki ^a   Bouton Verville, Hilary ^a   Xia, Shi Mao ^a   Newman, Amanda ^a   Ouyang, Ying Bin ^b   Haynes, Barton F ^a   Verkoczy, Laurent ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Taconic Farms Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2F5 PROTEIN; 4E10 PROTEIN; B LYMPHOCYTE RECEPTOR; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; LIPID; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CELL CYCLE ARREST; CONTROLLED STUDY; CROSS REACTION; FEMALE; HEAVY CHAIN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNE DEFICIENCY; HYBRIDOMA; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; STRAIN DIFFERENCE; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CELL DIFFERENTIATION; CROSS REACTIONS; GENE KNOCK-IN TECHNIQUES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; LIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, B-CELL;

EID: 84880667257     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300770     Document Type: Article

References (70)

1. McElrath, M. J., and B. F. Haynes. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
2. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210.
3. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009. Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
4. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins, and D. R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5: e1000433.
5. Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins, and D. R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membraneproximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84: 1302-1313.
6. Balazs, A. B., J. Chen, C. M. Hong, D. S. Rao, L. Yang, and D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
7. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11: 615-622.
8. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10: 11-23.
9. Haynes, B. F., G. Kelsoe, S. C. Harrison, and T. B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30: 423-433.
10. Verkoczy, L., G. Kelsoe, M. A. Moody, and B. F. Haynes. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23: 383-390.
11. Haynes, B. F., and D. C. Montefiori. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5: 579-595.
12. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
13. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100: 4144-4149.
14. Kwong, P. D., M. L. Doyle, D. J. Casper, C. Cicala, S. A. Leavitt, S. Majeed, T. D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptorbinding sites. Nature 420: 678-682.
15. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
16. Labrijn, A. F., P. Poignard, A. Raja, M. B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C. C. Huang, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77: 10557-10565.
17. Frey, G., H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, and B. Chen. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 105: 3739-3744.
18. Binley, J. M., Y. E. Ban, E. T. Crooks, D. Eggink, K. Osawa, W. R. Schief, and R. W. Sanders. 2010. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 84: 5637-5655.
19. Schief, W. R., Y. E. Ban, and L. Stamatatos. 2009. Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 4: 431-440.
20. Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15: 866-870.
21. Bonsignori, M., S. M. Alam, H. X. Liao, L. Verkoczy, G. D. Tomaras, B. F. Haynes, and M. A. Moody. 2012. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 20: 532-539.
22. Haynes, B. F., M. A. Moody, L. Verkoczy, G. Kelsoe, and S. M. Alam. 2005. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14: 59-67.
23. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67: 6642-6647.
24. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17: 1757-1765.
25. Haynes, B. F., J. Fleming, E. W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
26. Nemazee, D. A., and K. Bürki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
27. Erikson, J., M. Z. Radic, S. A. Camper, R. R. Hardy, C. Carmack, and M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in nonautoimmune mice. Nature 349: 331-334.
28. Goodnow, C. C. 1992. Transgenic mice and analysis of B-cell tolerance. Annu. Rev. Immunol. 10: 489-518.
29. Tiegs, S. L., D. M. Russell, and D. Nemazee. 1993. Receptor editing in selfreactive bone marrow B cells. J. Exp. Med. 177: 1009-1020.
30. Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177: 999-1008.
31. Verkoczy, L., M. Diaz, T. M. Holl, Y. B. Ouyang, H. Bouton-Verville, S. M. Alam, H. X. Liao, G. Kelsoe, and B. F. Haynes. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. USA 107: 181-186.
32. Verkoczy, L., Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y. B. Ouyang, S. M. Alam, T. M. Holl, K. K. Hwang, et al. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J. Immunol. 187: 3785-3797.
33. Cambier, J. C., S. B. Gauld, K. T. Merrell, and B. J. Vilen. 2007. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat. Rev. Immunol. 7: 633-643.
34. Hartley, S. B., J. Crosbie, R. Brink, A. B. Kantor, A. Basten, and C. C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353: 765-769.
35. Chen, C., Z. Nagy, M. Z. Radic, R. R. Hardy, D. Huszar, S. A. Camper, and M. Weigert. 1995. The site and stage of anti-DNA B-cell deletion. Nature 373: 252-255.
36. Montero, M., N. E. van Houten, X. Wang, and J. K. Scott. 2008. The membraneproximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72: 54-84.
37. Zwick, M. B., H. K. Komori, R. L. Stanfield, S. Church, M. Wang, P. W. Parren, R. Kunert, H. Katinger, I. A. Wilson, and D. R. Burton. 2004. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78: 3155-3161.
38. Yang, G., T. M. Holl, Y. Liu, Y. Li, X. Lu, N. I. Nicely, T. B. Kepler, S. M. Alam, H. X. Liao, D. W. Cain, et al. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210: 241-256.
39. Verkoczy, L., M. A. Moody, T. M. Holl, H. Bouton-Verville, R. M. Scearce, J. Hutchinson, S. M. Alam, G. Kelsoe, and B. F. Haynes. 2009. Functional, nonclonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS ONE 4: e7215.
40. Tiller, T., C. E. Busse, and H. Wardemann. 2009. Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350: 183-193.
41. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67: 3978-3988.
42. Hardy, R. R. 2006. B-1 B cell development. J. Immunol. 177: 2749-2754.
43. Li, Y., H. Li, and M. Weigert. 2002. Autoreactive B cells in the marginal zone that express dual receptors. J. Exp. Med. 195: 181-188.
44. Goodnow, C. C., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael, et al. 1988. Altered immunoglobulin expression and functional silencing of selfreactive B lymphocytes in transgenic mice. Nature 334: 676-682.
45. Goodnow, C. C., R. Brink, and E. Adams. 1991. Breakdown of self-tolerance in anergic B lymphocytes. Nature 352: 532-536.
46. Merrell, K. T., R. J. Benschop, S. B. Gauld, K. Aviszus, D. Decote-Ricardo, L. J. Wysocki, and J. C. Cambier. 2006. Identification of anergic B cells within a wild-type repertoire. Immunity 25: 953-962.
47. Roark, J. H., A. Bui, K. A. Nguyen, L. Mandik, and J. Erikson. 1997. Persistence of functionally compromised anti-double-stranded DNA B cells in the periphery of non-Autoimmune mice. Int. Immunol. 9: 1615-1626.
48. Nguyen, K. A., L. Mandik, A. Bui, J. Kavaler, A. Norvell, J. G. Monroe, J. H. Roark, and J. Erikson. 1997. Characterization of anti-single-stranded DNA B cells in a non-Autoimmune background. J. Immunol. 159: 2633-2644.
49. Rojas, M., C. Hulbert, and J. W. Thomas. 2001. Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen. J. Immunol. 166: 3194-3200.
50. Culton, D. A., B. P. O'Conner, K. L. Conway, R. Diz, J. Rutan, B. J. Vilen, and S. H. Clarke. 2006. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J. Immunol. 176: 790-802.
51. Borrero, M., and S. H. Clarke. 2002. Low-Affinity anti-Smith antigen B cells are regulated by anergy as opposed to developmental arrest or differentiation to B-1. J. Immunol. 168: 13-21.
52. Kilmon, M. A., J. A. Rutan, S. H. Clarke, and B. J. Vilen. 2005. Low-Affinity, Smith antigen-specific B cells are tolerized by dendritic cells and macrophages. J. Immunol. 175: 37-41.
53. Acevedo-Suárez, C. A., D. M. Kilkenny, M. B. Reich, and J. W. Thomas. 2006. Impaired intracellular calcium mobilization and NFATc1 availability in tolerant anti-insulin B cells. J. Immunol. 177: 2234-2241.
54. Sánchez-Martínez, S., M. Lorizate, H. Katinger, R. Kunert, and J. L. Nieva. 2006. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res. Hum. Retroviruses 22: 998-1006.
55. Scherer, E. M., M. B. Zwick, L. Teyton, and D. R. Burton. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21: 2131-2139.
56. Alam, S. M., M. Morelli, S. M. Dennison, H. X. Liao, R. Zhang, S. M. Xia, S. Rits-Volloch, L. Sun, S. C. Harrison, B. F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 106: 20234-20239.
57. Li, H., Y. Jiang, E. L. Prak, M. Radic, and M. Weigert. 2001. Editors and editing of anti-DNA receptors. Immunity 15: 947-957.
58. Minegishi, Y., and M. E. Conley. 2001. Negative selection at the pre-BCR checkpoint elicited by human mu heavy chains with unusual CDR3 regions. Immunity 14: 631-641.
59. Ivanov, I. I., R. L. Schelonka, Y. Zhuang, G. L. Gartland, M. Zemlin, and H. W. Schroeder, Jr. 2005. Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J. Immunol. 174: 7773-7780.
60. Martin, D. A., H. Bradl, T. J. Collins, E. Roth, H. M. Jäck, and G. E. Wu. 2003. Selection of Ig mu heavy chains by complementarity-determining region 3 length and amino acid composition. J. Immunol. 171: 4663-4671.
61. Wang, H., J. Ye, L. W. Arnold, S. K. McCray, and S. H. Clarke. 2001. A VH12 transgenic mouse exhibits defects in pre-B cell development and is unable to make IgM+ B cells. J. Immunol. 167: 1254-1262.
62. von Boehmer, H., and F. Melchers. 2010. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 11: 14-20.
63. Vettermann, C., and H. M. Jäck. 2010. The pre-B cell receptor: turning autoreactivity into self-defense. Trends Immunol. 31: 176-183.
64. Herzog, S., and H. Jumaa. 2012. Self-recognition and clonal selection: autoreactivity drives the generation of B cells. Curr. Opin. Immunol. 24: 166-172.
65. Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
66. Alam, S. M., H. X. Liao, S. M. Dennison, F. Jaeger, R. Parks, K. Anasti, A. Foulger, M. Donathan, J. Lucas, L. Verkoczy, et al. 2011. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 85: 11725-11731.
67. Ota, T., C. Doyle-Cooper, A. B. Cooper, M. Huber, E. Falkowska, K. J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, et al. 2012. Anti-HIV B Cell lines as candidate vaccine biosensors. J. Immunol. 189: 4816-4824.
68. Péron, S., B. Laffleur, N. Denis-Lagache, J. Cook-Moreau, A. Tinguely, L. Delpy, Y. Denizot, E. Pinaud, and M. Cogné. 2012. AID-driven deletion causes immunoglobulin heavy chain locus suicide recombination in B cells. Science 336: 931-934.
69. Jiang, C., M. L. Zhao, R. M. Scearce, and M. Diaz. 2011. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheum. 63: 1086-1096.
70. Zhang, Z., M. Zemlin, Y. H. Wang, D. Munfus, L. E. Huye, H. W. Findley, S. L. Bridges, D. B. Roth, P. D. Burrows, and M. D. Cooper. 2003. Contribution of Vh gene replacement to the primary B cell repertoire. Immunity 19: 21-31.